Regulatory
Sep 01, 2026 · 1 min read · 89,266 views
Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections
I
Isabella Hart
Editorial · Sep 01, 2026
Replimune can finally feel a sense of vindication. After two rejections, public clashing with the previous FDA leaders and a closed-door meeting with the White House, the
← Previous
BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen
Next →
Lack of biosimilar development could cost billions in lost savings, report warns
